NO304268B1 - FremgangsmÕte for fremstilling av et protein med aminosyresekvens som bestÕr av deler av aminosyre-sekvensen til hepatitt B-virus-stort (L) protein, vertscelle transformert med DNA som koder for proteinet, samt anvendelse av et protein eventuelt - Google Patents

FremgangsmÕte for fremstilling av et protein med aminosyresekvens som bestÕr av deler av aminosyre-sekvensen til hepatitt B-virus-stort (L) protein, vertscelle transformert med DNA som koder for proteinet, samt anvendelse av et protein eventuelt Download PDF

Info

Publication number: NO304268B1
Authority: NO; Norway
Prior art keywords: protein; expression; dna; pres; gene
Prior art date: 1989-07-25

Application number

NO903285A

Other languages

English (en)

Norwegian (no)

Other versions

NO903285L (no

NO903285D0 (no

Inventor

Martin Comberbach

Nigel Harford

Teresa Cabezon

Apolonia Rutgers

Pierre Voet

Eric Jacobs

Cornelis P Hollenberg

Zbigniew A Janowicz

Armin J Merckelbach

Original Assignee

Smithkline Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-25

Filing date

1990-07-24

Publication date

1998-11-23

1990-07-24 Application filed by Smithkline Biolog filed Critical Smithkline Biolog

1990-07-24 Publication of NO903285D0 publication Critical patent/NO903285D0/no

1991-01-28 Publication of NO903285L publication Critical patent/NO903285L/no

1998-11-23 Publication of NO304268B1 publication Critical patent/NO304268B1/no

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 320
102000004169 proteins and genes Human genes 0.000 title claims abstract description 224
238000000034 method Methods 0.000 title claims description 99
241000700721 Hepatitis B virus Species 0.000 title claims description 60
125000003275 alpha amino acid group Chemical group 0.000 title claims description 22
230000008569 process Effects 0.000 title description 4
230000014509 gene expression Effects 0.000 claims abstract description 250
101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims abstract description 173
239000002245 particle Substances 0.000 claims abstract description 152
240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 122
102100031673 Corneodesmosin Human genes 0.000 claims abstract description 92
108091007433 antigens Proteins 0.000 claims abstract description 81
102000036639 antigens Human genes 0.000 claims abstract description 80
239000000427 antigen Substances 0.000 claims abstract description 75
239000011246 composite particle Substances 0.000 claims abstract description 40
208000002672 hepatitis B Diseases 0.000 claims abstract description 36
239000013598 vector Substances 0.000 claims description 98
108020004414 DNA Proteins 0.000 claims description 88
108091026890 Coding region Proteins 0.000 claims description 87
239000000284 extract Substances 0.000 claims description 79
101710139375 Corneodesmosin Proteins 0.000 claims description 78
239000000203 mixture Substances 0.000 claims description 51
230000009466 transformation Effects 0.000 claims description 40
241000235648 Pichia Species 0.000 claims description 32
230000001105 regulatory effect Effects 0.000 claims description 31
108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
239000003550 marker Substances 0.000 claims description 24
238000004519 manufacturing process Methods 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 19
239000001963 growth medium Substances 0.000 claims description 13
108020004511 Recombinant DNA Proteins 0.000 claims description 10
101710137302 Surface antigen S Proteins 0.000 claims description 9
239000003153 chemical reaction reagent Substances 0.000 claims description 8
241000222120 Candida <Saccharomycetales> Species 0.000 claims description 7
239000013604 expression vector Substances 0.000 claims description 7
241000235070 Saccharomyces Species 0.000 claims description 6
238000012360 testing method Methods 0.000 claims description 6
239000013592 cell lysate Substances 0.000 claims description 5
230000002103 transcriptional effect Effects 0.000 claims description 4
241000235649 Kluyveromyces Species 0.000 claims description 3
241000235346 Schizosaccharomyces Species 0.000 claims description 3
238000000338 in vitro Methods 0.000 claims description 3
239000012472 biological sample Substances 0.000 claims description 2
241000125500 Hedypnois rhagadioloides Species 0.000 claims 1
241000320412 Ogataea angusta Species 0.000 abstract description 104
108090000765 processed proteins & peptides Proteins 0.000 abstract description 54
102000004196 processed proteins & peptides Human genes 0.000 abstract description 47
229920001184 polypeptide Polymers 0.000 abstract description 45
229960005486 vaccine Drugs 0.000 abstract description 35
108010031318 Vitronectin Proteins 0.000 abstract description 18
229940096437 Protein S Drugs 0.000 abstract description 17
230000000890 antigenic effect Effects 0.000 abstract description 12
230000004071 biological effect Effects 0.000 abstract description 12
150000002632 lipids Chemical class 0.000 abstract description 7
230000001976 improved effect Effects 0.000 abstract description 2
239000013612 plasmid Substances 0.000 description 193
210000004027 cell Anatomy 0.000 description 166
239000012634 fragment Substances 0.000 description 146
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 119
101150115433 SLC26A5 gene Proteins 0.000 description 115
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 115
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 57
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 53
238000010276 construction Methods 0.000 description 48
108010025188 Alcohol oxidase Proteins 0.000 description 43
150000001413 amino acids Chemical class 0.000 description 39
238000004458 analytical method Methods 0.000 description 39
239000000463 material Substances 0.000 description 39
108020004705 Codon Proteins 0.000 description 33
238000003119 immunoblot Methods 0.000 description 33
101150050575 URA3 gene Proteins 0.000 description 32
101150010882 S gene Proteins 0.000 description 30
238000011534 incubation Methods 0.000 description 30
239000002609 medium Substances 0.000 description 28
238000001514 detection method Methods 0.000 description 25
230000003362 replicative effect Effects 0.000 description 25
230000015572 biosynthetic process Effects 0.000 description 24
238000006243 chemical reaction Methods 0.000 description 24
210000005253 yeast cell Anatomy 0.000 description 24
239000002953 phosphate buffered saline Substances 0.000 description 23
238000001262 western blot Methods 0.000 description 23
238000003556 assay Methods 0.000 description 22
238000002474 experimental method Methods 0.000 description 21
238000013518 transcription Methods 0.000 description 21
230000035897 transcription Effects 0.000 description 21
241000700605 Viruses Species 0.000 description 20
238000005119 centrifugation Methods 0.000 description 20
244000005700 microbiome Species 0.000 description 20
239000000287 crude extract Substances 0.000 description 19
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
108700026244 Open Reading Frames Proteins 0.000 description 17
230000013595 glycosylation Effects 0.000 description 16
238000006206 glycosylation reaction Methods 0.000 description 16
229910052799 carbon Inorganic materials 0.000 description 15
230000007717 exclusion Effects 0.000 description 15
230000010354 integration Effects 0.000 description 15
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
241000588724 Escherichia coli Species 0.000 description 14
102100031004 Histidine-tRNA ligase, cytoplasmic Human genes 0.000 description 14
101000843187 Homo sapiens Histidine-tRNA ligase, cytoplasmic Proteins 0.000 description 14
241000699670 Mus sp. Species 0.000 description 14
108091003079 Bovine Serum Albumin Proteins 0.000 description 13
229920001213 Polysorbate 20 Polymers 0.000 description 13
208000015181 infectious disease Diseases 0.000 description 13
238000003780 insertion Methods 0.000 description 13
230000037431 insertion Effects 0.000 description 13
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 13
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 13
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 12
229930182566 Gentamicin Natural products 0.000 description 12
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 12
102100027377 HBS1-like protein Human genes 0.000 description 12
101001009070 Homo sapiens HBS1-like protein Proteins 0.000 description 12
241000276498 Pollachius virens Species 0.000 description 12
238000002105 Southern blotting Methods 0.000 description 12
239000000872 buffer Substances 0.000 description 12
108091008146 restriction endonucleases Proteins 0.000 description 12
230000014616 translation Effects 0.000 description 12
101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 11
235000019750 Crude protein Nutrition 0.000 description 11
102000004190 Enzymes Human genes 0.000 description 11
108090000790 Enzymes Proteins 0.000 description 11
108091034117 Oligonucleotide Proteins 0.000 description 11
108091005804 Peptidases Proteins 0.000 description 11
239000004365 Protease Substances 0.000 description 11
229930006000 Sucrose Natural products 0.000 description 11
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
238000012217 deletion Methods 0.000 description 11
230000037430 deletion Effects 0.000 description 11
230000029087 digestion Effects 0.000 description 11
230000000694 effects Effects 0.000 description 11
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 11
230000012010 growth Effects 0.000 description 11
238000002955 isolation Methods 0.000 description 11
229930027917 kanamycin Natural products 0.000 description 11
229960000318 kanamycin Drugs 0.000 description 11
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 11
229930182823 kanamycin A Natural products 0.000 description 11
210000004962 mammalian cell Anatomy 0.000 description 11
239000005720 sucrose Substances 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
238000012286 ELISA Assay Methods 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 10
210000000349 chromosome Anatomy 0.000 description 10
238000010790 dilution Methods 0.000 description 10
239000012895 dilution Substances 0.000 description 10
238000002372 labelling Methods 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 9
229940098773 bovine serum albumin Drugs 0.000 description 9
238000010367 cloning Methods 0.000 description 9
230000000717 retained effect Effects 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
108010001336 Horseradish Peroxidase Proteins 0.000 description 8
108090001030 Lipoproteins Proteins 0.000 description 8
102000004895 Lipoproteins Human genes 0.000 description 8
239000000020 Nitrocellulose Substances 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
125000000539 amino acid group Chemical group 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
229920001220 nitrocellulos Polymers 0.000 description 8
238000003752 polymerase chain reaction Methods 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
210000002845 virion Anatomy 0.000 description 8
102000053602 DNA Human genes 0.000 description 7
108010042407 Endonucleases Proteins 0.000 description 7
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
101150023946 MOX gene Proteins 0.000 description 7
230000033228 biological regulation Effects 0.000 description 7
229960000074 biopharmaceutical Drugs 0.000 description 7
238000000432 density-gradient centrifugation Methods 0.000 description 7
238000011161 development Methods 0.000 description 7
238000011049 filling Methods 0.000 description 7
239000008188 pellet Substances 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
108091006905 Human Serum Albumin Proteins 0.000 description 6
102000008100 Human Serum Albumin Human genes 0.000 description 6
108010052285 Membrane Proteins Proteins 0.000 description 6
102000018697 Membrane Proteins Human genes 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
239000011543 agarose gel Substances 0.000 description 6
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000007796 conventional method Methods 0.000 description 6
239000013613 expression plasmid Substances 0.000 description 6
238000001502 gel electrophoresis Methods 0.000 description 6
208000006454 hepatitis Diseases 0.000 description 6
231100000283 hepatitis Toxicity 0.000 description 6
229940126619 mouse monoclonal antibody Drugs 0.000 description 6
238000001243 protein synthesis Methods 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
239000000523 sample Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000013519 translation Methods 0.000 description 6
108090000204 Dipeptidase 1 Proteins 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
102000004533 Endonucleases Human genes 0.000 description 5
206010019799 Hepatitis viral Diseases 0.000 description 5
101710085938 Matrix protein Proteins 0.000 description 5
101710127721 Membrane protein Proteins 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000004186 co-expression Effects 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
238000000855 fermentation Methods 0.000 description 5
230000004151 fermentation Effects 0.000 description 5
230000006870 function Effects 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
230000003053 immunization Effects 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
230000006698 induction Effects 0.000 description 5
230000000394 mitotic effect Effects 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 5
230000004224 protection Effects 0.000 description 5
230000006798 recombination Effects 0.000 description 5
238000005215 recombination Methods 0.000 description 5
230000010076 replication Effects 0.000 description 5
239000006152 selective media Substances 0.000 description 5
201000001862 viral hepatitis Diseases 0.000 description 5
FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 4
102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
102000012410 DNA Ligases Human genes 0.000 description 4
108010061982 DNA Ligases Proteins 0.000 description 4
238000001712 DNA sequencing Methods 0.000 description 4
101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
241000282412 Homo Species 0.000 description 4
101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
101150007280 LEU2 gene Proteins 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 4
YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
238000003149 assay kit Methods 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
229910052802 copper Inorganic materials 0.000 description 4
239000010949 copper Substances 0.000 description 4
230000002950 deficient Effects 0.000 description 4
230000008030 elimination Effects 0.000 description 4
238000003379 elimination reaction Methods 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
239000008103 glucose Substances 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
238000001114 immunoprecipitation Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000011835 investigation Methods 0.000 description 4
238000001738 isopycnic centrifugation Methods 0.000 description 4
208000019423 liver disease Diseases 0.000 description 4
238000012423 maintenance Methods 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
238000003906 pulsed field gel electrophoresis Methods 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
238000013207 serial dilution Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
230000014621 translational initiation Effects 0.000 description 4
ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 4
MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
238000005406 washing Methods 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
239000003298 DNA probe Substances 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
101710091045 Envelope protein Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241001149669 Hanseniaspora Species 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
230000004988 N-glycosylation Effects 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
101710188315 Protein X Proteins 0.000 description 3
241000223252 Rhodotorula Species 0.000 description 3
241000700618 Vaccinia virus Species 0.000 description 3
239000011324 bead Substances 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
229960005091 chloramphenicol Drugs 0.000 description 3
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
230000002759 chromosomal effect Effects 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000002131 composite material Substances 0.000 description 3
238000001493 electron microscopy Methods 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
108010045673 endodeoxyribonuclease XBAI Proteins 0.000 description 3
230000004927 fusion Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
206010073071 hepatocellular carcinoma Diseases 0.000 description 3
238000002744 homologous recombination Methods 0.000 description 3
230000006801 homologous recombination Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
102000035118 modified proteins Human genes 0.000 description 3
108091005573 modified proteins Proteins 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
230000007498 myristoylation Effects 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000003252 repetitive effect Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000004062 sedimentation Methods 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
239000012798 spherical particle Substances 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
244000252363 Amydrium medium Species 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108010092265 CCWGG-specific type II deoxyribonucleases Proteins 0.000 description 2
108010053835 Catalase Proteins 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
101150073323 DAS gene Proteins 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
108060002716 Exonuclease Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
108700007698 Genetic Terminator Regions Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
241000235058 Komagataella pastoris Species 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
235000021360 Myristic acid Nutrition 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
241001494479 Pecora Species 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
101150006914 TRP1 gene Proteins 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
101710120037 Toxin CcdB Proteins 0.000 description 2
LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000008272 agar Substances 0.000 description 2
238000000246 agarose gel electrophoresis Methods 0.000 description 2
229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
150000001721 carbon Chemical class 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
239000008119 colloidal silica Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
102000013165 exonuclease Human genes 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229910001679 gibbsite Inorganic materials 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
230000002480 immunoprotective effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
241000514897 mixed subtypes Species 0.000 description 2
239000000178 monomer Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
150000002482 oligosaccharides Chemical group 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
230000008447 perception Effects 0.000 description 2
238000000164 protein isolation Methods 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
238000001472 pulsed field gradient Methods 0.000 description 2
230000008439 repair process Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000005204 segregation Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
229940048086 sodium pyrophosphate Drugs 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000000856 sucrose gradient centrifugation Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
230000001629 suppression Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
230000006490 viral transcription Effects 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
101150005709 ARG4 gene Proteins 0.000 description 1
229910002019 Aerosil® 380 Inorganic materials 0.000 description 1
VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
101500018099 Apis mellifera ARMGFHGMR-amide Proteins 0.000 description 1
101100163849 Arabidopsis thaliana ARS1 gene Proteins 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
108010031540 CCGCGG-specific type II deoxyribonucleases Proteins 0.000 description 1
101100291031 Caenorhabditis elegans gly-13 gene Proteins 0.000 description 1
101100245267 Caenorhabditis elegans pas-1 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
102000004031 Carboxy-Lyases Human genes 0.000 description 1
108090000489 Carboxy-Lyases Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
101100538048 Colletotrichum orbiculare (strain 104-T / ATCC 96160 / CBS 514.97 / LARS 414 / MAFF 240422) TRM8 gene Proteins 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
101710093617 Dihydroxyacetone synthase Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
108090000698 Formate Dehydrogenases Proteins 0.000 description 1
108010058643 Fungal Proteins Proteins 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
108010026624 GTCGAC-specific type II deoxyribonucleases Proteins 0.000 description 1
241000250507 Gigaspora candida Species 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
102000005744 Glycoside Hydrolases Human genes 0.000 description 1
108010031186 Glycoside Hydrolases Proteins 0.000 description 1
101150074178 HNT2 gene Proteins 0.000 description 1
244000286779 Hansenula anomala Species 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
101150062031 L gene Proteins 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
101710084021 Large envelope protein Proteins 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241001460678 Napo <wasp> Species 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
108010066124 Protein S Proteins 0.000 description 1
102000029301 Protein S Human genes 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
101100097319 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ala1 gene Proteins 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KYOBSHFOBAOFBF-UHFFFAOYSA-N UMP Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-UHFFFAOYSA-N 0.000 description 1
COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
240000004922 Vigna radiata Species 0.000 description 1
235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
101100004044 Vigna radiata var. radiata AUX22B gene Proteins 0.000 description 1
241000222124 [Candida] boidinii Species 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000005273 aeration Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
101150089041 aph-1 gene Proteins 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000010310 bacterial transformation Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000009172 bursting Effects 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
101150095218 der gene Proteins 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
210000001840 diploid cell Anatomy 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
238000000635 electron micrograph Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
229940124736 hepatitis-B vaccine Drugs 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
230000000652 homosexual effect Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000004201 immune sera Anatomy 0.000 description 1
229940042743 immune sera Drugs 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000001320 lysogenic effect Effects 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
230000013011 mating Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
239000000401 methanolic extract Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000037435 normal mutation Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
KYOBSHFOBAOFBF-ZAKLUEHWSA-N orotidine-5'-monophosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-ZAKLUEHWSA-N 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
230000009984 peri-natal effect Effects 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
108010002730 protein S precursor Proteins 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
239000013014 purified material Substances 0.000 description 1
101150116440 pyrF gene Proteins 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000037425 regulation of transcription Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
108091035233 repetitive DNA sequence Proteins 0.000 description 1
102000053632 repetitive DNA sequence Human genes 0.000 description 1
230000001718 repressive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
239000007320 rich medium Substances 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
PVFDPMYXCZLHKY-MLLWLMKGSA-M sodium [(1R,2R,4aR,8aS)-2-hydroxy-5-[(2E)-2-[(4S)-4-hydroxy-2-oxooxolan-3-ylidene]ethyl]-1,4a,6-trimethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl sulfate Chemical compound [Na+].C([C@@H]1[C@](C)(COS([O-])(=O)=O)[C@H](O)CC[C@]11C)CC(C)=C1C\C=C1/[C@H](O)COC1=O PVFDPMYXCZLHKY-MLLWLMKGSA-M 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000002336 sorption--desorption measurement Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
MEYZYGMYMLNUHJ-DIRMKAHISA-N tunicamycin B2 Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](C[C@@H](O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CCCCCCCCCC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O MEYZYGMYMLNUHJ-DIRMKAHISA-N 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Mycology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Compounds Of Unknown Constitution (AREA)

NO903285A 1989-07-25 1990-07-24 FremgangsmÕte for fremstilling av et protein med aminosyresekvens som bestÕr av deler av aminosyre-sekvensen til hepatitt B-virus-stort (L) protein, vertscelle transformert med DNA som koder for proteinet, samt anvendelse av et protein eventuelt NO304268B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38534289A	1989-07-25	1989-07-25
US38918489A	1989-08-03	1989-08-03

Publications (3)

Publication Number	Publication Date
NO903285D0 NO903285D0 (no)	1990-07-24
NO903285L NO903285L (no)	1991-01-28
NO304268B1 true NO304268B1 (no)	1998-11-23

Family

ID=27010975

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO903285A NO304268B1 (no)	1989-07-25	1990-07-24	FremgangsmÕte for fremstilling av et protein med aminosyresekvens som bestÕr av deler av aminosyre-sekvensen til hepatitt B-virus-stort (L) protein, vertscelle transformert med DNA som koder for proteinet, samt anvendelse av et protein eventuelt

Country Status (21)

Country	Link
EP (1)	EP0414374B1 (de)
JP (1)	JP3069907B2 (de)
KR (1)	KR0181940B1 (de)
CN (1)	CN1080304C (de)
AT (1)	ATE159031T1 (de)
AU (3)	AU5972890A (de)
CA (1)	CA2021762C (de)
DE (1)	DE69031556T2 (de)
DK (1)	DK0414374T3 (de)
ES (1)	ES2109921T3 (de)
FI (1)	FI903721A7 (de)
GR (1)	GR3025819T3 (de)
HU (1)	HU216013B (de)
IE (1)	IE902690A1 (de)
IL (1)	IL95153A0 (de)
MA (1)	MA21911A1 (de)
NO (1)	NO304268B1 (de)
NZ (1)	NZ234615A (de)
PL (1)	PL168597B1 (de)
PT (1)	PT94791B (de)
SG (1)	SG48175A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0300213A1 (de) *	1987-06-22	1989-01-25	Hexal-Pharma Gentechnik GmbH & Co. KG	Virale, immunogen wirksame Peptidpartikel von Hepatitis A
PL168787B1 (pl) *	1989-08-03	1996-04-30	Smithkline Beecham Biolog	Sposób wytwarzania czastki kompozytowej PL
EP0491077A1 (de) *	1990-12-19	1992-06-24	Medeva Holdings B.V.	Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
IL101651A0 (en) *	1991-04-29	1992-12-30	Merck & Co Inc	Hepatitis b virus surface proteins with reduced host carbohydrate content
IL101653A0 (en) *	1991-04-29	1992-12-30	Merck & Co Inc	Multiple hepatitis b virus surface proteins which form particles
MA22842A1 (fr) *	1992-03-27	1993-10-01	Smithkline Beecham Biolog	Procede de preparation de compositions de vaccin.
US6620414B2 (en)	1992-03-27	2003-09-16	Smithkline Beecham Biologicals (S.A.)	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
DE69319728T2 (de)	1992-05-23	1999-02-04	Smithkline Beecham Biologicals S.A., Rixensart	Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
CA2138997C (en)	1992-06-25	2003-06-03	Jean-Paul Prieels	Vaccine composition containing adjuvants
SG48309A1 (en) *	1993-03-23	1998-04-17	Smithkline Beecham Biolog	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
AT409863B (de) *	1993-07-30	2002-12-27	Immuno Ag	Hoch effiziente expression eines polypeptids, das eine modifizierte pres1-region des grossen hepatitis b-virus-antigens enthält
US6488934B1 (en)	1995-02-25	2002-12-03	Smithkline Beecham Biologicals S.A.	Hepatitis B vaccine
GB9503863D0 (en) *	1995-02-25	1995-04-19	Smithkline Beecham Biolog	Vaccine compositions
US5658579A (en) *	1995-07-31	1997-08-19	The Procter & Gamble Company	Cosmetic powder compositions having improved skin coverage
GB9623233D0 (en)	1996-11-07	1997-01-08	Smithkline Beecham Biolog	Vaccine composition
KR100372233B1 (ko) *	1997-03-12	2003-06-11	주식회사 코리아나화장품	미백 파우더, 그의 제조방법 및 그를 함유하는 메이크업 미백 화장료
AU750587B2 (en)	1998-10-16	2002-07-25	Smithkline Beecham Biologicals (Sa)	Adjuvant systems and vaccines
JP2002534438A (ja) *	1999-01-12	2002-10-15	スミスクラインビーチャムバイオロジカルズソシエテアノニム	新規治療法
FR2803599B1 (fr) *	2000-01-06	2004-11-19	Inst Nat Sante Rech Med	Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
GB0109297D0 (en)	2001-04-12	2001-05-30	Glaxosmithkline Biolog Sa	Vaccine
DE602004031681D1 (de)	2003-07-21	2011-04-14	Transgene Sa	Multifunktionelle Cytokine
US7851433B2 (en)	2003-08-13	2010-12-14	Novartis Vaccines And Diagnostics, Inc.	Method of purifying TFPI and TFPI analogs
BRPI0610297A2 (pt)	2005-04-18	2010-06-08	Novartis Vaccines & Diagnostic	expressão de antìgeno de superfìcie de vìrus da hepatite b para a preparação de vacina
GB0522765D0 (en)	2005-11-08	2005-12-14	Chiron Srl	Combination vaccine manufacture
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
EA015964B1 (ru)	2006-09-07	2012-01-30	Глаксосмитклайн Байолоджикалс С.А.	Вакцина
KR101378872B1 (ko)	2006-09-26	2014-04-11	인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이)	합성 애주번트를 함유하는 백신 조성물
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
EP2433648A3 (de)	2006-10-12	2012-04-04	GlaxoSmithKline Biologicals S.A.	Impfstoff mit einem Öl-in-wasser-emulsionshilfsstoff
ES2397714T3 (es)	2006-10-12	2013-03-08	Glaxosmithkline Biologicals S.A.	Vacuna que comprende un adyuvante de emulsión de aceite en agua
PE20090146A1 (es)	2007-04-20	2009-03-23	Glaxosmithkline Biolog Sa	Composicion inmunogenica contra el virus influenza
EA201490303A1 (ru)	2007-05-02	2014-05-30	Глаксосмитклайн Байолоджикалс С.А.	Вакцина
SI2437753T1 (sl)	2009-06-05	2016-12-30	Infectious Disease Research Institute	Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
CN102038948B (zh) *	2009-10-10	2013-04-10	复旦大学	一种控制乙型肝炎病毒持续性感染的疫苗
EP2489724A4 (de) *	2009-10-16	2013-05-01	Kaneka Corp	Zur produktion von antikörpern geeignete hansenula polymorpha, antikörperherstellungsverfahren damit und in diesem verfahren hergestellte antikörper
NZ602892A (en)	2010-04-13	2014-08-29	Celldex Therapeutics Inc	Antibodies that bind human cd27 and uses thereof
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
AU2012243039B2 (en)	2011-04-08	2017-07-13	Immune Design Corp.	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN103087933B (zh) *	2011-11-08	2015-07-22	北京生物制品研究所	一种重组多形汉逊酵母菌及其制备方法
CN110339160A (zh)	2012-02-07	2019-10-18	传染性疾病研究院	包含tlr4激动剂的改进佐剂制剂及其使用方法
CN102643349B (zh) *	2012-04-17	2013-12-18	中国医学科学院医学生物学研究所	携带乙肝病毒抗原表位的重组嵌合蛋白及其制备
PT2850431T (pt)	2012-05-16	2018-07-23	Immune Design Corp	Vacinas para hsv-2
EP3587455A1 (de)	2012-10-23	2020-01-01	Emory University	Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
EP3711768A1 (de)	2013-04-18	2020-09-23	Immune Design Corp.	Gla-monotherapie zur verwendung in der krebsbehandlung
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
IL310015B2 (en)	2013-12-31	2026-02-01	Access To Advanced Health Inst	Single vial formulation
EP3268037B1 (de)	2015-03-09	2022-08-31	Celldex Therapeutics, Inc.	Cd27 agonists
CN105797151A (zh) *	2016-03-25	2016-07-27	汪和睦	一种基于重组汉逊酵母的高剂量乙型肝炎疫苗
JP7038064B2 (ja)	2016-04-18	2022-03-17	セルデックスセラピューティクスインコーポレイテッド	ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
EP4112638A1 (de)	2016-05-16	2023-01-04	Access to Advanced Health Institute	Formulierung mit tlr-agonist und verfahren zur verwendung
IL263030B2 (en)	2016-05-16	2024-11-01	Access To Advanced Health Inst	Pegylated liposomes and methods of use
KR102748354B1 (ko)	2016-06-01	2024-12-31	액세스 투 어드밴스드 헬스 인스티튜트	사이징제를 함유하는 나노명반 입자
KR102673794B1 (ko)	2017-06-15	2024-06-11	액세스 투 어드밴스드 헬스 인스티튜트	나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
CN111315406A (zh)	2017-09-08	2020-06-19	传染病研究所	包括皂苷的脂质体调配物及其使用方法
WO2019204462A2 (en)	2018-04-17	2019-10-24	Celldex Therapeutics, Inc.	Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
WO2020123444A1 (en)	2018-12-11	2020-06-18	Celldex Therapeutics, Inc.	Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
BR112021023726A2 (pt)	2019-05-25	2022-02-15	Infectious Disease Res Inst	Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
CA3174411A1 (en)	2020-09-04	2022-03-10	Ryan M. Kramer	Co-lyophilized rna and nanostructured lipid carrier
EP4320159A1 (de)	2021-04-09	2024-02-14	Celldex Therapeutics, Inc.	Antikörper gegen ilt4, bispezifische anti-ilt4/pd-l1-antikörper und verwendungen davon
WO2023077521A1 (en)	2021-11-08	2023-05-11	Celldex Therapeutics, Inc	Anti-ilt4 and anti-pd-1 bispecific constructs
EP4583841A1 (de)	2022-09-09	2025-07-16	Access to Advanced Health Institute	Immunogene impfstoffzusammensetzung mit einem saponin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0288198A3 (de) *	1987-04-20	1989-03-29	Takeda Chemical Industries, Ltd.	Peptidherstellung

1990
- 1990-07-19 EP EP90307900A patent/EP0414374B1/de not_active Expired - Lifetime
- 1990-07-19 DE DE69031556T patent/DE69031556T2/de not_active Expired - Fee Related
- 1990-07-19 DK DK90307900.2T patent/DK0414374T3/da active
- 1990-07-19 AT AT90307900T patent/ATE159031T1/de not_active IP Right Cessation
- 1990-07-19 ES ES90307900T patent/ES2109921T3/es not_active Expired - Lifetime
- 1990-07-19 SG SG1996007620A patent/SG48175A1/en unknown
- 1990-07-23 CA CA002021762A patent/CA2021762C/en not_active Expired - Fee Related
- 1990-07-23 AU AU59728/90A patent/AU5972890A/en not_active Abandoned
- 1990-07-23 IL IL95153A patent/IL95153A0/xx unknown
- 1990-07-23 MA MA22181A patent/MA21911A1/fr unknown
- 1990-07-23 PT PT94791A patent/PT94791B/pt not_active IP Right Cessation
- 1990-07-23 NZ NZ234615A patent/NZ234615A/xx unknown
- 1990-07-24 NO NO903285A patent/NO304268B1/no not_active IP Right Cessation
- 1990-07-24 FI FI903721A patent/FI903721A7/fi not_active Application Discontinuation
- 1990-07-24 IE IE269090A patent/IE902690A1/en unknown
- 1990-07-24 KR KR1019900011386A patent/KR0181940B1/ko not_active Expired - Fee Related
- 1990-07-25 CN CN90107172A patent/CN1080304C/zh not_active Expired - Fee Related
- 1990-07-25 JP JP2197578A patent/JP3069907B2/ja not_active Expired - Lifetime
- 1990-07-25 PL PL90286209A patent/PL168597B1/pl unknown
- 1990-07-25 HU HU4615/90A patent/HU216013B/hu not_active IP Right Cessation
1994
- 1994-10-28 AU AU77528/94A patent/AU7752894A/en not_active Abandoned
1997
- 1997-04-18 AU AU18968/97A patent/AU714652B2/en not_active Ceased
- 1997-12-30 GR GR970403469T patent/GR3025819T3/el unknown

Also Published As

Publication number	Publication date
DE69031556T2 (de)	1998-05-14
HU216013B (hu)	1999-04-28
NO903285L (no)	1991-01-28
AU7752894A (en)	1995-02-16
CN1080304C (zh)	2002-03-06
PL168597B1 (pl)	1996-03-29
HUT57266A (en)	1991-11-28
IL95153A0 (en)	1991-06-10
CA2021762A1 (en)	1991-01-26
AU5972890A (en)	1991-01-31
KR910003103A (ko)	1991-02-26
JPH0380083A (ja)	1991-04-04
JP3069907B2 (ja)	2000-07-24
DE69031556D1 (de)	1997-11-13
CA2021762C (en)	2000-09-12
PL286209A1 (en)	1991-04-08
NZ234615A (en)	1992-12-23
PT94791A (pt)	1991-03-20
HK1003032A1 (en)	1998-09-30
SG48175A1 (en)	1998-04-17
CN1052331A (zh)	1991-06-19
IE902690A1 (en)	1991-02-27
FI903721A7 (fi)	1991-01-26
NO903285D0 (no)	1990-07-24
EP0414374A3 (en)	1992-12-16
EP0414374A2 (de)	1991-02-27
MA21911A1 (fr)	1991-04-01
GR3025819T3 (en)	1998-03-31
DK0414374T3 (da)	1998-03-09
EP0414374B1 (de)	1997-10-08
PT94791B (pt)	1997-09-30
HU904615D0 (en)	1991-01-28
FI903721A0 (fi)	1990-07-24
ES2109921T3 (es)	1998-02-01
AU1896897A (en)	1997-06-19
ATE159031T1 (de)	1997-10-15
KR0181940B1 (ko)	1999-04-01
AU714652B2 (en)	2000-01-06

Legal Events

Date	Code	Title	Description
2003-03-10	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN JANUARY 2003

Publication	Publication Date	Title
CA2021762C (en)	2000-09-12	Antigens and methods therefor
DK169152B1 (da)	1994-08-29	Fremgangsmåde til fremstilling af et antistof mod HBsAg
AP56A (en)	1989-09-26	Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP0522030B1 (de)	1995-08-02	Vakzin gegen hepatitis b
US4769238A (en)	1988-09-06	Synthesis of human virus antigens by yeast
US6103519A (en)	2000-08-15	Antigens and methods therefor
EP0511854A1 (de)	1992-11-04	Partikeln bildende multiple Hepatitis-B-Virus-Oberflächen-Proteine
NZ229260A (en)	1994-02-25	Hepatitis b virus, expression cassette for pre-s domain, host cells and
EP0533263A2 (de)	1993-03-24	Vielwertiges Vakzin gegen B-Hepatitis-Virus
Kniskern et al.	1989	The application of molecular biology to the development of novel vaccines
WO1994001132A1 (en)	1994-01-20	VACCINE COMPRISING MIXED preS1+preS2+S AND CORE PARTICLE
HK1003032B (en)	1998-09-30	Novel antigens and methods for their preparation
EP0340806B1 (de)	1995-05-31	Synthese von menschlichen Virusantigenen durch Hefe
AU642729C (en)	1998-08-27	Hepatitis B vaccine
Maigetter et al.	2013	Montgomery LD Schultz CA. Schulman CE Carty
IE67139B1 (en)	1996-03-06	Synthesis of human virus antigens by yeast
NZ242984A (en)	1994-02-25	Recombinant production of hepatitis b virus protein. (51) c07k15/04;